Meeting
2019 Genitourinary Cancers Symposium
Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.
Authors
Adam G. Sowalsky
National Cancer Institute, Bethesda, MD
Adam G. Sowalsky , Scott Wilkinson , Huihui Ye , Stephanie Harmon , Baris Turkbey , Nicole Carrabba , Rayann Atway , Guinevere Chun , David James VanderWeele , Fatima Karzai , Ravi Amrit Madan , Peter A. Pinto , Peter L. Choyke , William L. Dahut
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT02430480
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 61)
DOI
10.1200/JCO.2019.37.7_suppl.61
Abstract #
61
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).
First Author: Fatima Karzai
Poster
2018 ASCO Annual Meeting
Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.
First Author: David James VanderWeele
Poster
2018 Genitourinary Cancers Symposium
Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).
First Author: Rana R. McKay
Poster
2015 Genitourinary Cancers Symposium
Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes.
First Author: Felix Yi-Chung Feng